ЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ ИНФЛИКСИМАБОМ РЕЗИСТЕНТНЫХ ФОРМ ЮВЕНИЛЬНОГО РЕВМАТОИДНОГО АРТРИТА
Алексеева Екатерина Иосифовна, А М Алексеева, Tatyana M. Bzarova et al. · CyberLeninK (CyberLeninka) · 2006
The purpose of this open study was to evaluate efficacy and safety of infliximab, an antiatnfa ?monoclonal antibody, in 37 children with juvenile idiopathic arthritis (JIA). Group 1 comprised 16 patients with severe longaterm jia with systemic onset. Group 2 comprised 21 patients with oligoa and polyarticular JIA. Groups were matched in demographic features. The follow up period has ranged between 6 weeks and 2 years. All children received infliximab and concomitant D mard therapy, 3 of them received oral glucocorticoids. Inflixa imab with a mean dose of 6,5 ± 0,3 mg/kg was administered intravenously at baseline, 2, 6 and every 8 week. Infliximab has shown statistically significant improvement (p < 0,01) in all patients with early oligoa and polyarticular JIA (group 2). Remission following the second infusion (at the 3 week of observation) has been registered in all patients with oligoa and polyarticular jia, meanwhile in patients with systemic JIA remission has been registered only in 2 cases at a time of 7 months of treatment with infliximab. Eight (50%) patients from group 1 and 2 children (9,5%) from group 2 discontinued infliximab due to inefficacy. 5 (24%) of patients from group 2 developed side effects that led to infliximab discontinuation. Therefore, the therapy with infliximab has proved to be sound, safe and effective with best results in patients with oligoa and polyarticular jia. Key words: juvenile rheumatoid arthritis, infliximab, children.
Cited by 0 works.
Authors
References
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
- Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
- Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
- Rheumatoid Arthritis
- Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.
- Pathogenesis of rheumatoid arthritis